BRPI0915888E2 - polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso - Google Patents
polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu usoInfo
- Publication number
- BRPI0915888E2 BRPI0915888E2 BRC10915888A BRPI0915888A BRPI0915888E2 BR PI0915888 E2 BRPI0915888 E2 BR PI0915888E2 BR C10915888 A BRC10915888 A BR C10915888A BR PI0915888 A BRPI0915888 A BR PI0915888A BR PI0915888 E2 BRPI0915888 E2 BR PI0915888E2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor
- polypeptide
- acid sequence
- nucleic acid
- sequence encoding
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000007523 nucleic acids Chemical group 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 108010073466 Bombesin Receptors Proteins 0.000 abstract 1
- 102100030851 Cortistatin Human genes 0.000 abstract 1
- 229930185483 Cortistatin Natural products 0.000 abstract 1
- 108010016122 Ghrelin Receptors Proteins 0.000 abstract 1
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 abstract 1
- 101710198286 Growth hormone-releasing hormone receptor Proteins 0.000 abstract 1
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 abstract 1
- 102100034845 KiSS-1 receptor Human genes 0.000 abstract 1
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 abstract 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 abstract 1
- 102000056271 Prolactin-releasing peptide receptors Human genes 0.000 abstract 1
- 108700024163 Prolactin-releasing peptide receptors Proteins 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 101150056450 UTS2R gene Proteins 0.000 abstract 1
- 108010005430 cortistatin Proteins 0.000 abstract 1
- 108091008039 hormone receptors Proteins 0.000 abstract 1
- 208000015706 neuroendocrine disease Diseases 0.000 abstract 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 abstract 1
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 1
- 231100000065 noncytotoxic Toxicity 0.000 abstract 1
- 230000002020 noncytotoxic effect Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0810782.3A GB0810782D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of cancers |
| GB0810785.6 | 2008-06-12 | ||
| GB0810785A GB0810785D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of neuroendocrine diseases |
| GB0810782.3 | 2008-06-12 | ||
| GB0820884.5 | 2008-11-14 | ||
| GB0820884A GB0820884D0 (en) | 2008-11-14 | 2008-11-14 | Suppression of neuroendocrine diseases |
| GB0820965.2 | 2008-11-17 | ||
| GB0820965A GB0820965D0 (en) | 2008-11-17 | 2008-11-17 | Suppression of cancers |
| PCT/GB2009/050665 WO2009150469A2 (en) | 2008-06-12 | 2009-06-11 | Suppression of neuroendocrine diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0915888A2 BRPI0915888A2 (pt) | 2020-06-30 |
| BRPI0915888E2 true BRPI0915888E2 (pt) | 2020-09-01 |
Family
ID=41417177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRC10915888A BRPI0915888E2 (pt) | 2008-06-12 | 2009-06-11 | polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso |
Country Status (12)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| US10466245B2 (en) | 2008-02-20 | 2019-11-05 | The Secretary Of State For Health | Covalently linked thermostable kinase for decontamination process validation |
| GB0803068D0 (en) | 2008-02-20 | 2008-03-26 | Health Prot Agency | Cross-linked biological indicator |
| JP5728380B2 (ja) * | 2008-06-12 | 2015-06-03 | シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ | 神経内分泌疾患の抑制 |
| GB0820970D0 (en) * | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| US10407730B2 (en) * | 2014-09-15 | 2019-09-10 | Clifton Life Sciences LLC | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm |
| BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| WO2016061583A1 (en) * | 2014-10-17 | 2016-04-21 | University Of Virginia Patent Foundation | Compositions and methods for treating pituitary tumors |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| CN109790204A (zh) | 2016-09-29 | 2019-05-21 | 益普生生物制药有限公司 | 杂合神经毒素 |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| EP3375871A1 (en) * | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Selective cell death-inducing enzyme system |
| AU2018275685B2 (en) * | 2017-05-31 | 2025-04-17 | Napo Pharmaceuticals, Inc. | Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome |
| BR112020006827A2 (pt) | 2018-01-29 | 2020-10-06 | Ipsen Biopharm Limited | neurotoxinas botulínicas clivando snare não neuronal |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| CN110801512B (zh) * | 2019-11-15 | 2023-07-18 | 中国水产科学研究院黑龙江水产研究所 | 一种用于促进哲罗鲑性腺成熟的多肽及其应用 |
| CN111388651B (zh) * | 2020-05-09 | 2022-05-03 | 山东大学齐鲁医院 | Cst-14在制备骨质疏松症治疗药物中的应用 |
| CN113257370B (zh) * | 2021-05-12 | 2022-09-02 | 中国医学科学院北京协和医院 | 基于临床病理基本信息和vista检测的pnet复发风险预测模型 |
| WO2025155896A1 (en) * | 2024-01-19 | 2025-07-24 | Sling Therapeutics, Inc. | Use of inhibitors of insulin-like growth factor receptor-1 for growth hormone igf-secreting neoplasias |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
| US4133782A (en) | 1976-06-07 | 1979-01-09 | The Salk Institute For Biological Studies | Somatostatin analogs with dissociated biological activities |
| US4190575A (en) | 1977-12-27 | 1980-02-26 | American Home Products Corporation | Polypeptides related to somatostatin |
| DE2860734D1 (en) | 1977-06-08 | 1981-09-03 | Merck & Co Inc | Somatostatin analogs, process for their preparation and pharmaceutical compositions containing them |
| US4211693A (en) | 1977-09-20 | 1980-07-08 | The Salk Institute For Biological Studies | Peptides with para-substituted phenylalanine |
| LU78191A1 (de) | 1977-09-28 | 1979-05-25 | Ciba Geigy Ag | Verfahren zur herstellung von neuen cyclopeptiden |
| JPS5819669B2 (ja) | 1978-10-28 | 1983-04-19 | 白井松新薬株式会社 | 新規生理活性ペプチド化合物及びその製造法 |
| US4190648A (en) | 1979-03-13 | 1980-02-26 | Merck & Co., Inc. | Peptides having somatostatin activity |
| US4316890A (en) | 1979-03-16 | 1982-02-23 | Ciba-Geigy Corporation | Peptides and processes for the manufacture thereof |
| US4328214A (en) | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4369179A (en) | 1979-12-14 | 1983-01-18 | Ciba-Geigy Corporation | Acylpeptides |
| US4282143A (en) | 1980-06-13 | 1981-08-04 | American Home Products Corporation | Octapeptides lowering growth hormone |
| US4360516A (en) | 1981-04-13 | 1982-11-23 | Merck & Co., Inc. | Modified D-retro cyclic hexapeptide somatostatin analogs |
| DE3264693D1 (en) | 1981-12-24 | 1985-08-14 | Ciba Geigy Ag | Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use |
| FR2522655B1 (fr) | 1982-03-05 | 1987-03-06 | Sanofi Sa | Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant |
| US4522813A (en) | 1983-10-27 | 1985-06-11 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4659693A (en) | 1984-04-30 | 1987-04-21 | Syntex (U.S.A.) Inc. | N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides |
| US4632979A (en) | 1984-06-18 | 1986-12-30 | Tulane Educational Fund | Therapeutic LHRH analogs |
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| US5003011A (en) | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4650787A (en) | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
| US4725577A (en) | 1985-04-25 | 1988-02-16 | Administrators Of The Tulane Educational Fund | Biologically active lysine containing octapeptides |
| US4585755A (en) | 1985-04-29 | 1986-04-29 | Merck & Co., Inc. | Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents |
| US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4803261A (en) | 1986-06-27 | 1989-02-07 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide |
| HU206890B (en) | 1986-10-13 | 1993-01-28 | Sandoz Ag | Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components |
| US4871717A (en) | 1987-01-07 | 1989-10-03 | Administrators Of The Tulane Educational Fund | Peptides |
| WO1989002897A1 (en) | 1987-09-24 | 1989-04-06 | The Administrators Of The Tulane Educational Fund | Therapeutic peptides |
| US5084555A (en) | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
| EP0329295A1 (en) | 1988-02-01 | 1989-08-23 | The Upjohn Company | Renin inhibiting peptides with polar end groups |
| NO893088L (no) | 1988-08-18 | 1990-02-19 | Syntex Inc | Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| JP2919889B2 (ja) | 1988-10-14 | 1999-07-19 | アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド | 治療用ペプチド |
| US5171835A (en) | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| CA2012115C (en) | 1989-03-15 | 2001-07-03 | Biomeasure, Inc. | Iodinated somatostatins |
| CA2053250A1 (en) | 1989-04-26 | 1990-10-27 | David H. Coy | Linear somatostatin analogs |
| WO1991009056A1 (en) | 1989-12-08 | 1991-06-27 | The Administrators Of The Tulane Educational Fund | Octapeptide analogs of somatostatin having threonine at the sixth position |
| ATE127476T1 (de) | 1990-04-06 | 1995-09-15 | Univ Tulane | Lhrh-analoge. |
| WO1991016923A1 (en) | 1990-05-04 | 1991-11-14 | The Administrators Of The Tulane University Educational Fund | Novel synthetic grf analogs |
| CA2081890A1 (en) | 1990-05-09 | 1991-11-10 | David H. Coy | Cyclized and linear therapeutic peptides |
| IT1240643B (it) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| HU207104B (en) | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
| US6083915A (en) | 1991-05-10 | 2000-07-04 | Biomeasure, Inc. | Method for treating liver cancer |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| US5240561A (en) | 1992-02-10 | 1993-08-31 | Industrial Progress, Inc. | Acid-to-alkaline papermaking process |
| US5656727A (en) | 1992-09-15 | 1997-08-12 | The Administrators Of The Tulane Educational Fund | Antagonists of LHRH |
| AU5668894A (en) | 1992-11-13 | 1994-06-08 | The Administrators Of The Tulane Eductional Fund | Ghrh agonists |
| WO1994011397A1 (en) | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
| GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| EP1288224B1 (en) | 1993-08-09 | 2008-06-25 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Therapeutic peptide derivatives |
| US5550212A (en) | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
| AUPM985694A0 (en) | 1994-12-02 | 1995-01-05 | Farmer, Mostyn | Golf training aid |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| ATE170873T1 (de) | 1995-03-13 | 1998-09-15 | Biomeasure Inc | Bombesin-analogen |
| CA2218173A1 (en) | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| US5942489A (en) | 1996-05-03 | 1999-08-24 | The Administrators Of The Tulane Educational Fund | HGH-RH(1-29)NH2 analogues having antagonistic activity |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| WO1998008528A1 (en) | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| US5968903A (en) | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
| KR100580541B1 (ko) | 1998-05-13 | 2006-05-16 | 비오테크콘 게젤샤프트 퓌어 비오테크놀로지셰 엔트리클룽 운트 콘술팅 엠베하 | 비만세포의 과립소실을 억제하기 위한 혼성 단백질 및 그사용방법 |
| WO2000004926A2 (en) | 1998-07-22 | 2000-02-03 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
| IL140837A0 (en) | 1998-07-30 | 2002-02-10 | Sod Conseils Rech Applic | Method of using lanreotide, a somatostatin analogue |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| CN1367793A (zh) | 1999-06-04 | 2002-09-04 | 研究及应用科学协会股份有限公司 | 神经调节肽b和生长抑素受体拮抗剂 |
| US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| EP2267008B1 (en) * | 1999-08-25 | 2014-07-02 | Allergan, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US20030180289A1 (en) * | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
| US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6827931B1 (en) * | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| WO2004076634A2 (en) * | 2003-02-24 | 2004-09-10 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease |
| TW200517400A (en) * | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| EP1982997B1 (en) * | 2004-09-01 | 2012-08-08 | Allergan, Inc. | Degradable clostridial toxins |
| CA2595115C (en) * | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| EP1861419B1 (en) * | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DK2154151T3 (da) | 2005-09-19 | 2011-09-05 | Allergan Inc | Clostridiumtoksinaktiverbare clostridiumtoksiner |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| WO2008008805A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| JP5728380B2 (ja) * | 2008-06-12 | 2015-06-03 | シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ | 神経内分泌疾患の抑制 |
| BRPI0915142A8 (pt) * | 2008-06-12 | 2018-01-02 | Syntaxin Ltd | Polipeptídeos, ácido nucleico e usos dos mesmos |
| US10057187B1 (en) | 2015-05-27 | 2018-08-21 | Amazon Technologies, Inc. | Dynamic resource creation to connect client resources in a distributed system |
-
2009
- 2009-06-11 JP JP2011513056A patent/JP5728380B2/ja active Active
- 2009-06-11 BR BRC10915888A patent/BRPI0915888E2/pt not_active IP Right Cessation
- 2009-06-11 CN CN201410295607.7A patent/CN104328100B/zh not_active Expired - Fee Related
- 2009-06-11 EP EP09762018.1A patent/EP2310028B1/en active Active
- 2009-06-11 KR KR1020117000251A patent/KR101642363B1/ko not_active Expired - Fee Related
- 2009-06-11 ES ES13179177T patent/ES2750651T3/es active Active
- 2009-06-11 AU AU2009259033A patent/AU2009259033B2/en not_active Ceased
- 2009-06-11 WO PCT/GB2009/050665 patent/WO2009150469A2/en not_active Ceased
- 2009-06-11 EP EP19175007.4A patent/EP3590956A1/en active Pending
- 2009-06-11 CN CN200980130069.3A patent/CN102112145B/zh not_active Expired - Fee Related
- 2009-06-11 US US12/996,643 patent/US20110171191A1/en not_active Abandoned
- 2009-06-11 CA CA2727082A patent/CA2727082C/en not_active Expired - Fee Related
- 2009-06-11 EP EP13179177.4A patent/EP2719392B1/en active Active
- 2009-06-11 ES ES09762018.1T patent/ES2614990T3/es active Active
-
2010
- 2010-11-29 ZA ZA2010/08536A patent/ZA201008536B/en unknown
- 2010-12-08 IL IL209855A patent/IL209855A/en not_active IP Right Cessation
-
2014
- 2014-04-21 JP JP2014087047A patent/JP5891258B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009150469A3 (en) | 2010-07-15 |
| ES2750651T3 (es) | 2020-03-26 |
| CN102112145B (zh) | 2014-07-30 |
| IL209855A0 (en) | 2011-02-28 |
| CN104328100A (zh) | 2015-02-04 |
| KR20110038017A (ko) | 2011-04-13 |
| ES2614990T3 (es) | 2017-06-02 |
| EP3590956A1 (en) | 2020-01-08 |
| WO2009150469A2 (en) | 2009-12-17 |
| JP5728380B2 (ja) | 2015-06-03 |
| EP2719392A1 (en) | 2014-04-16 |
| KR101642363B1 (ko) | 2016-07-25 |
| CN102112145A (zh) | 2011-06-29 |
| BRPI0915888A2 (pt) | 2020-06-30 |
| CA2727082C (en) | 2019-02-26 |
| US20110171191A1 (en) | 2011-07-14 |
| ZA201008536B (en) | 2012-05-30 |
| JP2011522560A (ja) | 2011-08-04 |
| AU2009259033B2 (en) | 2013-11-07 |
| EP2719392B1 (en) | 2019-07-24 |
| AU2009259033A1 (en) | 2009-12-17 |
| CN104328100B (zh) | 2019-08-23 |
| IL209855A (en) | 2013-09-30 |
| EP2310028B1 (en) | 2016-11-16 |
| CA2727082A1 (en) | 2009-12-17 |
| JP5891258B2 (ja) | 2016-03-22 |
| EP2310028A2 (en) | 2011-04-20 |
| JP2014195454A (ja) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL209855A (en) | Polypeptide, an amino acid sequence encoded for this polypeptide, and the use of this polypeptide to prepare a drug for the treatment of acromegaly | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| WO2009105671A3 (en) | Methods and compositions related to peptides and proteins with c-terminal elements | |
| CY1118038T1 (el) | Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος | |
| BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
| CL2012001685A1 (es) | Análogo peptídico de oxintomodulina, en donde el aminoácido c-terminal es opcionalmente amidado; composición farmacéutica que lo comprende; y su uso en la preparación de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad. | |
| BRPI0316092B8 (pt) | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos | |
| CL2012000119A1 (es) | Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus. | |
| GT200900229A (es) | Coagonistas de receptor de glucagón/glp-1 | |
| WO2006097536A3 (en) | Dimeric peptide agonists of the glp-1 receptor | |
| IL209854A (en) | Polypeptide, an amino acid sequence encoded for this polypeptide, and the use of this polypeptide for the preparation of a cancer suppressant | |
| WO2010010551A3 (en) | Angiopoietin derived peptides | |
| GT201200189A (es) | Antagonistas de pcsk9 | |
| CY1118200T1 (el) | Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης | |
| PL1972637T3 (pl) | Antagoniści selektywni wobec huTNFR1 | |
| AR077764A1 (es) | Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos | |
| WO2008079973A9 (en) | Egfr binding peptides and uses thereof | |
| CL2008002727A1 (es) | Composicion que comprende un polipeptido de glandula salival de anophles gambiae, y metodo de produccion; constructo de polipeptido y contructo de acido nucleico, y metodo de produccion; composicion de vacuna o medicamento y metodo de produccion; uso para tratar o prevenir una enfermedad transmitida por artoropodos | |
| MX2018006299A (es) | Analogos de peptido de la hormona de estimulacion de alfa-melanocito. | |
| PE20070033A1 (es) | Concentrado de proteina y flujo acuoso que contiene carbohidratos solubles de agua | |
| CL2012001656A1 (es) | Polipéptido de somatotropina bovina que comprende uno o mas aminoácidos no naturales y que estan ligados a un polimero soluble en agua. composicion farmaceutica que comprende dichos polipeptidos. | |
| WO2009034315A3 (en) | Vaccine | |
| AR100768A1 (es) | Método para disminuir la inmunogenicidad de proteínas y péptidos | |
| WO2009081368A3 (en) | Cosmetic use desmoglein i-type proteins | |
| BRPI0607097A2 (pt) | peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: IPSEN BIOINNOVATION LIMITED (GB) |
|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B25G | Requested change of headquarter approved |
Owner name: IPSEN BIOINNOVATION LIMITED (GB) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |